ABOUT US

Innovative Biochips is a spin-off company from Houston Texas Medical Center (TMC), a rich environment that places unique assets and a wealth of resources at the disposal of all investigators and researchers in life science field.

Innovative Biochips is committed to develop advanced microfluidic technologies that resolve traditional biotech challenges by achieving cutting-edge sensitivity and high-throughput. The company’s scientists and engineers have extensive and successful experience in developing novel microfluidic technologies for various biological and biomedical applications.

Innovative Biochips has currently 18 international distributors in Europe and Asia, and has engaged Fisher Scientific to sell its products in USA. Moreover, Innovative Biochips has established business collaboration with Thermo Fisher Scientific, Millipore Sigma, BioTek, and Harvard Bioscience that allows key benefits to drive product development.

Grants And Awards

Fierce Innovation Awards: Life Sciences Edition Announce Finalists, Innovative Biochips Recognized

Innovative Biochips has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition, an awards program from the publisher of FierceBiotech and FiercePharma. Innovative Biochips was recognized as a finalist in the category of Biotech Innovation.

Innovative Biochips, LLC Awarded Phase II Grant Support from the National Institutes of Health

Innovative Biochips, LLC Awarded Phase II Grant Support from the National Institutes of Health

Innovative Biochips, LLC has been awarded a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) Phase II grant.

This Phase II grant ($1,500,000) supports to continue the research and development efforts of Innovative Biochips for developing an automated dissection system initiated in Phase I grant ($225,000).

The Phase II funding is based on the results achieved in Phase I and the scientific and technical merit and commercial potential of the Phase II project proposed. Only Phase I awardees are eligible for a Phase II award.

Financial Conflicts of Interest Policy

This Policy implements Financial Conflicts of Interest (FCOI) disclosure requirements found in 42 CFR Part 50 and 45 CFR Part 94 which are applicable to Research funded by the U.S. Public Health Service (PHS).

As a condition for receiving PHS funding, these regulations require Innovative Biochips LLC to maintain an appropriate written policy on financial conflict of interest disclosure, and make such policy available via a publicly accessible Web site. The Innovative Biochips’ FCOI Policy and FCOI Disclosure Form can be found below.

• ​​Financial Conflict of Interest Policy
Financial Conflict of Interest Disclosure Form

PUBLICATIONS

Block-Cell-Printing for live single-cell printing.
Hand-Held and Integrated Single-Cell Pipettesa
CRISPR-Cas9 delivery to hard-to-transfect cells
via membrane deformation
High-throughput analysis of yeast replicative
aging using a microfluidic system
Multiplexed volumetric bar-chart chip for point-of-care diagnostics
Vertical cell pairing system for high-resolution imaging of immunological synapse and novel PD-1 dynamics
Microfluidics separation reveals the stem-cell–like deformability of tumor-initiating cells
Mesenchymal-Mode Migration Assay and Antimetastatic Drug Screening with High-Throughput Microfluidic Channel Networks
Rapid identification and drug susceptibility screening of ESAT-6 secreting Mycobacteria by a NanoELIwell assay
Point-of-care technologies for molecular diagnostics using a drop of blood

Media Coverage

Ancient Chinese woodblocks inspire new cell-printing technique
New live-cell printing technology works like ancient Chinese woodblocking
The Art and Science of Single-Cell Printing
Block-Cell Printing Bids to Improve on Inkjet Printing
New Cellular ‘Woodblock’ Printing Method Stamps Living Cells In Patterns
Membrane-Deforming Tool Makes for Easier CRISPR-based Gene Editing
Calorie-Restricted Yeast Live Longer
Tumor-Causing Cells Are Squishier
Enriching metastatic cells
Houston researcher invents device to easily capture a single cell
Houston Methodist Invention Wins R&D 100 Award
CRISPR-Cas9 delivery by microfluidics
Cutting calories lets yeast live longer